Board Member
Resmed Inc (RMD)Chief Accounting Officer
Becton Dickinson & Co (BDX)Equibles does not estimate personal net worth.
Get an email with a short summary when Resmed Inc publishes a filing, an earnings call transcript or a press release.
Get RMD alertsChristopher DelOrefice is recorded as Board Member at Resmed Inc (RMD) and Chief Accounting Officer at Becton Dickinson & Co (BDX) since August 30, 2024. The newest filing on record that lists Christopher DelOrefice as Board Member at Resmed Inc (RMD) is dated October 1, 2026. Resmed Inc reported in an 8-K filed November 20, 2025 that Christopher DelOrefice was appointed Director, effective November 19, 2025. Becton Dickinson & Co reported in an 8-K filed October 15, 2025 that Christopher DelOrefice resigned as Executive Vice President and Chief Financial Officer, effective December 5, 2025. Becton Dickinson & Co reported in an 8-K filed August 30, 2024 that Christopher DelOrefice was appointed principal accounting officer, effective August 30, 2024. Equibles holds 4 filed executive changes naming Christopher DelOrefice; each is listed under recent activity with its source filing. Christopher DelOrefice has spoken on 7 earnings calls across 1 company, most recently for Becton Dickinson & Co on November 6, 2025. Becton Dickinson & Co is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Resmed Inc is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Becton Dickinson & Co includes David F. Melcher (Chairman), Thomas E. Polen (Chairman and Board Member), Patrick K. Kaltenbach (CTO) and 7 others.
“elected the eleven nominees listed below to serve on our board of directors”
“On October 9, 2025, Christopher J. DelOrefice informed Becton, Dickinson and Company (the "Company" or "BD") of his intention to resign from his position as the Company's Executive Vice President and Chief Financial Officer effective December 5, 2025 to pursue a new professional opportunity.”
“Before I begin, I want to take a moment to thank the entire team at BD. It has been a privilege and a career highlight to serve as the CFO of this company and getting to work hand-in-hand with our talented and committed colleagues to advance the world of health.”
“Starting with our Q3 revenue performance. Revenues of $5.5 billion grew 8.5% or 3% organic. New BD organic growth was 4%. Regionally, total company organic growth was led by performance in the U.S. and Greater Asia outside of China, partially offset by China.”
“As Tom noted, we executed well on our performance goals in Q2. As expected, we delivered strong acceleration in our revenue growth, exceeded both our margin and earnings goals, and delivered very strong free cash flow growth.”
“As Tom noted, we executed well against our performance goals in Q1. Q1 revenue growth was largely as we expected, and I'm pleased to share we exceeded both our margin and earnings goals and delivered strong cash flow that positions us well to support our double-digit free cash flow growth goal.”
“Echoing Tom's comments, we delivered strong, consistent results this fiscal year, which reflects our growth strategy playing out as planned. Through execution of our BD 2025 strategy, we are fulfilling our short-term commitments while progressing towards our long-term goals.”
2024-08-30–present
Start not stated–present
Last confirmed October 1, 2026
2021-09-06–2025-12-05
Start not stated–2025-12-05
Medical Instruments & Supplies · Healthcare
Chief Accounting Officer
2021-09-06–present
